Hepatocellular Carcinoma: Current Management

Current Problems in Surgery

Volumn 47, Issue 1, 2010, Pages 10-67

  Cha, Charles H ^a   Saif, M Wasif ^b   Yamane, Brett H ^c   Weber, Sharon M ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ALCOHOL; ALPHA FETOPROTEIN; ALPHA INTERFERON; BLEOMYCIN; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IODINATED POPPYSEED OIL; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; NOLATREXED; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PLACEBO; POLYVINYL ALCOHOL; SORAFENIB; STARCH MICROSPHERE; TAMOXIFEN; UNINDEXED DRUG; YTTRIUM 90;

ABDOMINAL DISCOMFORT; ABDOMINAL RADIOGRAPHY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT INJURY; BLOATING; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; ECHOGRAPHY; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; ILEUS; INTERMETHOD COMPARISON; JAUNDICE; LAPAROSCOPIC SURGERY; LAPAROTOMY; LIVER ABSCESS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER RESECTION; LIVER SURGERY; LIVER TRANSPLANTATION; LIVING DONOR; MICROWAVE IRRADIATION; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAIN; PATIENT SELECTION; PREOPERATIVE EVALUATION; PROGNOSIS; RADIOFREQUENCY ABLATION; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; EMBOLIZATION, THERAPEUTIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 71049185598     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2009.09.003     Document Type: Article

References (255)

1. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
2. Okuda K., Kojiro M., Okuda H., et al. Neoplasms of the liver. Diseases of the Liver Vol. 7 (1993), Lippincott, Philadelphia 1236-1296
3. Attali P., Prod H., Pelletier G., et al. Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 59 (1987) 2108-2111
4. Calvet X., Bruix J., Gines P., et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 12 4 Pt 1 (1990) 753-760
5. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
6. Nagasue N., Yukaya H., Hamada T., et al. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54 (1984) 1461-1465
7. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 (1985) 918-928
8. Altekruse S.F., McGlynn K.A., and Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27 (2009) 1485-1491
9. Gupta S., Bent S., and Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 139 (2003) 46-50
10. Oka H., Tamori A., Kuroki T., et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19 (1994) 61-66
11. Pateron D., Ganne N., Trinchet J.C., et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 20 (1994) 65-71
12. Spangenberg H.C., Thimme R., and Blum H.E. Serum markers of hepatocellular carcinoma. Semin Liver Dis 26 (2006) 385-390
13. Wolf D.C. Screening for hepatocellular carcinoma: is it cost-effective?. Liver Transpl 9 (2003) 682-683
14. Izzo F., Cremona F., Ruffolo F., et al. Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. Ann Surg 227 (1998) 513-518
15. Chan A.C.Y., Poon R.T.P., Ng K.K.C., et al. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 247 (2008) 666-673
16. Curley S.A., Izzo F., Gallipoli A., et al. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg 222 (1995) 375-383
17. Del Pozo A.C., and Lopez P. Management of hepatocellular carcinoma. Clin Liver Dis 11 (2007) 305-321
18. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
19. Poon R.T., Fan S.T., Lo C.M., et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 240 (2004) 698-708 discussion 708-10
20. Llovet J.M., Schwartz M., and Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25 (2005) 181-200
21. Makuuchi M., and Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 10 2 Suppl 1 (2004) S46-S52
22. Child C.G., and Turcotte J.G. Surgery and portal hypertension. Major Probl Clin Surg 1 (1964) 1-85
23. Teh S., Christein J., Donohue J., et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9 (2005) 1207-1215
24. Cucchetti A., Ercolani G., Vivarelli M., et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 12 (2006) 966-971
25. Schroeder R.A., Marroquin C.E., Bute B.P., et al. Predictive indices of morbidity and mortality after liver resection. Ann Surg 243 (2006) 373-379
26. Lau H., Man K., Fan S.T., et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 84 (1997) 1255-1259
27. Hemming A.W., Scudamore C.H., Shackleton C.R., et al. Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg 163 (1992) 515-518
28. Matsumata T., Kanematsu T., Yoshida Y., et al. The indocyanine green test enables prediction of postoperative complications after hepatic resection. World J Surg 11 (1987) 678-681
29. Redaelli C.A., Dufour J.F., Wagner M., et al. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg 235 (2002) 77-85
30. Kokudo N., Vera D.R., Tada K., et al. Predictors of successful hepatic resection: prognostic usefulness of hepatic asialoglycoprotein receptor analysis. World J Surg 26 (2002) 1342-1347
31. Greene F.L., American Joint Committee on Cancer, and American Cancer Society. AJCC Cancer Staging Manual. 6th ed. (2002), Springer-Verlag, New York
32. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28 (1998) 751-755
33. Kudo M., Chung H., and Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38 (2003) 207-215
34. Bellavance E.C., Lumpkins K.M., Mentha G., et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation?. J Gastrointest Surg 12 (2008) 1699-1708
35. Huo T.I., Lin H.C., Hsia C.Y., et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 102 (2007) 1920-1930
36. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
37. Henderson J.M., Sherman M., Tavill A., et al. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB 5 (2003) 243-250
38. Tsuzuki T., Sugioka A., Ueda M., et al. Hepatic resection for hepatocellular carcinoma. Surgery 107 (1990) 511-520
39. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74 (1994) 2772-2780
40. Bismuth H., Chiche L., Adam R., et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218 (1993) 145-151
41. Bismuth H., Chiche L., and Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J Surg 19 (1995) 35-41
42. Fong Y., Sun R.L., Jarnagin W., and Blumgart L.H. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229 (1999) 790-799
43. Grazi G.L., Ercolani G., Pierangeli F., Del G., Cescon M., Cavallari A., et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 234 (2001) 71-78
44. Poon R.T., Fan S.T., Lo C.M., Liu C.L., Lam C.M., Yuen W.K., et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?. Ann Surg 236 (2002) 602-611
45. Esnaola N.F., Mirza N., Lauwers G.Y., Ikai I., Regimbeau J.M., Belghiti J., et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg 238 (2003) 711-719
46. Cha C., Fong Y., Jarnagin W.R., et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197 (2003) 753-758
47. Wu F.S., Zhao W.H., Liang T.B., Ma Z.M., Teng L.S., Wang M., et al. Survival factors after resection of small hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 4 (2005) 379-384
48. Nuzzo G., Giuliante F., Gauzolino R., Vellone M., Ardito F., and Giovannini I. Liver resections for hepatocellular carcinoma in chronic liver disease: experience in an Italian centre. Eur J Surg Oncol 33 (2007) 1014-1018
49. Katz S.C., Shia J., Liau K.H., et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 249 (2009) 617-623
50. Nathan H., Schulick R.D., Choti M.A., and Pawlik T.M. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249 (2009) 799-805
51. Llovet J.M., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
52. Ishizawa T., Hasegawa K., Aoki T., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134 (2008) 1908-1916
53. Kawano Y., Sasaki A., Kai S., et al. Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 15 (2008) 1670-1676
54. Abdalla E.K., Hicks M.E., and Vauthey J.N. Portal vein embolization: rationale, technique and future prospects. Br J Surg 88 (2001) 165-175
55. Farges O., Belghiti J., Kianmanesh R., et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237 (2003) 208-217
56. Abulkhir A., Limongelli P., Healey A.J., et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247 (2008) 49-57
57. Belghiti J., and Benhaïm L. Portal vein occlusion prior to extensive resection in colorectal liver metastasis: a necessity rather than an option!. Ann Surg Oncol 16 (2009) 1098-1099
58. Shi M., Guo R.P., Lin X.J., et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 245 (2007) 36-43
59. Cha C.H., Ruo L., Fong Y., et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 238 (2003) 315-321
60. Arii S., Yamaoka Y., Futagawa S., et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan The Liver Cancer Study Group of Japan. Hepatology 32 (2000) 1224-1229
61. Llovet J.M., and Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 38 Suppl 1 (2003) S136-S149
62. Ercolani G., Grazi G.L., Ravaioli M., et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237 (2003) 536-543
63. Shirabe K., Takenaka K., Taketomi A., et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 77 (1996) 1050-1055
64. Yamamoto J., Kosuge T., Takayama T., et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83 (1996) 1219-1222
65. Hu R.H., Lee P.H., Yu S.C., et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 120 (1996) 23-29
66. Minagawa M., Makuuchi M., Takayama T., and Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238 (2003) 703-710
67. Nagasue N., Yukaya H., Chang Y.C., et al. Assessment of pattern and treatment of intrahepatic recurrence after resection of hepatocellular carcinoma. Surg Gynecol Obstet 171 (1990) 217-222
68. Tang Z.Y., Yu Y.Q., Zhou X.D., et al. Surgery of small hepatocellular carcinoma. Analysis of 144 cases. Cancer 64 (1989) 536-541
69. Shimada M., Takenaka K., Gion T., et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 111 (1996) 720-726
70. Poon R.T.P. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 16 (2009) 792-794
71. Pawlik T.M., Poon R.T., Abdalla E.K., et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 140 (2005) 450-457 discussion 457-8
72. Choi G.H., Han D.H., Kim D.H., et al. Outcome after curative resection for a huge (>/=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg 198 (2009) 693-701
73. Liau K.H., Ruo L., Shia J., et al. Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. Cancer 104 (2005) 1948-1955
74. Shah S.A., Wei A.C., Cleary S.P., et al. Prognosis and results after resection of very large (>or=10 cm) hepatocellular carcinoma. J Gastrointest Surg 11 (2007) 589-595
75. Lei H.J., Chau G.Y., Lui W.Y., et al. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 203 (2006) 426-435
76. Vauthey J.N., Lauwers G.Y., Esnaola N.F., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 20 (2002) 1527-1536
77. Sun H.C., Zhuang P.Y., Qin L.X., et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 96 (2007) 37-45
78. Ercolani G., Grazi G.L., Ravaioli M., et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg 239 (2004) 202-209
79. Chen H.Y., Juan C.C., and Ker C.G. Laparoscopic liver surgery for patients with hepatocellular carcinoma. Ann Surg Oncol 15 (2008) 800-806
80. Belli G., Fantini C., D'Agostino A., et al. Laparoscopic versus open liver resection for hepatocellular carcinoma in patients with histologically proven cirrhosis: short- and middle-term results. Surg Endosc 21 (2007) 2004-2011
81. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 110 (1991) 726-734
82. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
83. De Carlis L., Giacomoni A., Pirotta V., et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg 196 (2003) 887-897
84. Hemming A.W., Cattral M.S., Reed A.I., et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 233 (2001) 652-659
85. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33 (2001) 1394-1403
86. Yoo H.Y., Patt C.H., Geschwind J.F., and Thuluvath P.J. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21 (2003) 4329-4335
87. Iwatsuki S., Starzl T.E., Sheahan D.G., Yokoyama I., Demetris A.J., Todo S., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214 (1991) 221-228
88. OPTN: Organ Procurement and Transplantation Network, Transplant: Transplant Year (2007-2008) by Diagnosis. http://optn.transplant.hrsa.gov/latestData/rptData.asp
89. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 246 (2007) 502-509 discussion 509-11
90. Roayaie K., and Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement?. Liver Transpl 13 11 Suppl 2 (2007) S36-S43
91. Poon R.T., Fan S.T., Ng I.O., and Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg 237 (2003) 376-383
92. Belghiti J., Cortes A., Abdalla E.K., et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238 (2003) 885-893
93. Llovet J.M., Mas X., Aponte J.J., et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50 (2002) 123-128
94. Poon R.T., Fan S.T., Lo C.M., et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235 (2002) 373-382
95. Adam R., Azoulay D., Castaing D., et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?. Ann Surg 238 (2003) 508-518
96. Bartlett A., and Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol 14 (2008) 4445-4453
97. Belghiti J. Resection and liver transplantation for HCC. J Gastroenterol 44 Suppl 19 (2009) 132-135
98. Hu R.H., Ho M.C., Wu Y.M., et al. Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin Transplant 19 (2005) 175-180
99. Kim B.W., Park Y.K., Kim Y.B., et al. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk. Transplant Proc 40 (2008) 3558-3561
100. Hwang S., Lee S.G., Joh J.W., et al. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 11 (2005) 1265-1272
101. Thuluvath P.J., and Yoo H.Y. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl 10 (2004) 1263-1268
102. Lo C.M., Fan S.T., Liu C.L., et al. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 10 (2004) 440-447
103. Fisher R.A., Kulik L.M., Freise C.E., et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7 (2007) 1601-1608
104. Lo C.M., Fan S.T., Liu C.L., et al. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 94 (2007) 78-86
105. Kulik L., and Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 127 5 Suppl 1 (2004) S277-S282
106. Gondolesi G., Munoz L., Matsumoto C., et al. Hepatocellular carcinoma: a prime indication for living donor liver transplantation. J Gastrointest Surg 6 (2002) 102-107
107. Kaihara S., Kiuchi T., Ueda M., et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 75 (2003) S37-S40
108. Schwartz M. Liver transplantation: the preferred treatment for early hepatocellular carcinoma in the setting of cirrhosis?. Ann Surg Oncol 14 (2007) 548-552
109. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
110. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
111. El-Serag H.B. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35 5 Suppl 2 (2002) S72-S78
112. Ibrahim S.M., Lewandowski R.J., Sato K.T., et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 14 (2008) 1664-1669
113. Garrean S., Hering J., Saied A., et al. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg 195 (2008) 508-520
114. Weber S.M., and Lee Jr. F.T. Expanded treatment of hepatic tumors with radiofrequency ablation and cryoablation. Oncology (Williston Park) 19 11 Suppl 4 (2005) 27-32
115. Liapi E., and Geschwind J.F. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 25 (2007) 978-986
116. Wallace J.R., Christians K.K., Quiroz F.A., et al. Ablation of liver metastasis: is preoperative imaging sufficiently accurate?. J Gastrointest Surg 5 (2001) 98-107
117. Cervone A., Sardi A., and Conaway G.L. Intraoperative ultrasound (IOUS) is essential in the management of metastatic colorectal liver lesions. Am Surg 66 (2000) 611-615
118. Chen M.S., Li J.Q., Zheng Y., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243 (2006) 321-328
119. Lau W.Y., and Lai E.C. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 249 (2009) 20-25
120. Curley S.A., Izzo F., Ellis L.M., et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232 (2000) 381-391
121. Liang P., and Wang Y. Microwave ablation of hepatocellular carcinoma. Oncology 72 Suppl 1 (2007) 124-131
122. Seki T., Wakabayashi M., Nakagawa T., et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74 (1994) 817-825
123. Liang P., Dong B., Yu X., et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 235 (2005) 299-307
124. Shibata T., Iimuro Y., Yamamoto Y., et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223 (2002) 331-337
125. Sugiura N., Takara K., Ohto M., et al. Ultrasound-guided ethanol injection for the treatment of small hepatocelluar carcinoma. Acta Hepatol Jpn 21 (1983) 923-3
126. Ebara M., Okabe S., Kita K., et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 43 (2005) 458-464
127. Lin X.D., and Lin L.W. Local injection therapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 5 (2006) 16-21
128. Guan Y.S., and Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 5 (2006) 495-500
129. Huang G.T., Lee P.H., Tsang Y.M., et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 242 (2005) 36-42
130. Livraghi T., Bolondi L., Buscarini L., et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 22 (1995) 522-526
131. Shiina S. Japanese experience in ablation therapies for hepatocellular carcinoma. Hepatol Res 37 Suppl 2 (2007) S223-S229
132. Sung Y.M., Choi D., Lim H.K., et al. Long-term results of percutaneous ethanol injection for the treatment of hepatocellular carcinoma in Korea. Korean J Radiol 7 (2006) 187-192
133. Lin S.M., Lin C.J., Lin C.C., et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54 (2005) 1151-1156
134. Cho Y.B., Lee K.U., Suh K.S., et al. Hepatic resection compared to percutaneous ethanol injection for small hepatocellular carcinoma using propensity score matching. J Gastroenterol Hepatol 22 (2007) 1643-1649
135. Gournay J., Tchuenbou J., Richou C., et al. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis. Aliment Pharmacol Ther 16 (2002) 1529-1538
136. Daniele B., De Sio I., Izzo F., et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol 36 (2003) 63-67
137. Cho Y.K., Kim J.K., Kim M.Y., et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49 (2009) 453-459
138. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104 (2009) 514-524
139. Pleguezuelo M., Germani G., Marelli L., et al. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2 (2008) 761-784
140. Brunello F., Veltri A., Carucci P., et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 43 (2008) 727-735
141. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 (2005) 122-130
142. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 127 (2004) 1714-1723
143. Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228 (2003) 235-240
144. Lim L., Gibbs P., Yip D., et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 35 (2005) 222-227
145. Park W., Lim D.H., Paik S.W., et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 1143-1150
146. Park H.C., Seong J., Han K.H., et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 54 (2002) 150-155
147. Eccles C., Brock K.K., Bissonnette J.P., et al. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys 64 (2006) 751-759
148. Herfarth K.K., Debus J., Lohr F., et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19 (2001) 164-170
149. Lawrence T.S., Robertson J.M., Anscher M.S., et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31 (1995) 1237-1248
150. Tokuuye K., Sumi M., Ikeda H., et al. Technical considerations for fractionated stereotactic radiotherapy of hepatocellular carcinoma. Jpn J Clin Oncol 27 (1997) 170-173
151. Wulf J., Guckenberger M., Haedinger U., et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 45 (2006) 838-847
152. Choi B.O., Jang H.S., Kang K.M., et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 36 (2006) 154-158
153. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18 (2000) 2210-2218
154. Tse R.V., Hawkins M., Lockwood G., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26 (2008) 657-664
155. Lim L., Gibbs P., Yip D., et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 5 (2005) 132
156. Salem R., Lewandowski R.J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16 (2005) 1627-1639
157. Sharma R.A., Van Hazel G.A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25 (2007) 1099-1106
158. Vogl T.J., Zangos S., Eichler K., et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 17 (2007) 1025-1034
159. Lau W.Y., Lai E.C., Leung T.W., and Yu S.C. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 247 (2008) 43-48
160. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
161. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
162. Zhou W.P., Lai E.C., Li A.J., et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 249 (2009) 195-202
163. Wu C.C., Ho Y.Z., Ho W.L., et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 82 (1995) 122-126
164. Yamasaki S., Hasegawa H., Kinoshita H., et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 87 (1996) 206-211
165. Lai E.C., Lo C.M., Fan S.T., et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133 (1998) 183-188
166. Izumi R., Shimizu K., Iyobe T., et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20 (1994) 295-301
167. Samuel M., Chow P.K., Chan Shih-Yen E., et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 1 (2009) CD001199
168. Takayasu K., Arii S., Ikai I., et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131 (2006) 461-469
169. Cheng B.Q., Jia C.Q., Liu C.T., et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 299 (2008) 1669-1677
170. Cheng J.C., Chuang V.P., Cheng S.H., et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 47 (2000) 435-442
171. Robertson J.M., Lawrence T.S., Andrews J.C., et al. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. Int J Radiat Oncol Biol Phys 37 (1997) 325-330
172. Seong J., Keum K.C., Han K.H., et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 393-397
173. Ngan H., Lai C.L., Fan S.T., et al. Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. J Vasc Interv Radiol 7 (1996) 419-425
174. Yang C.F., and Ho Y.J. Transcatheter arterial chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 31 Suppl (1992) S86-S88
175. Yamada R., Sato M., Kawabata M., et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148 (1983) 397-401
176. Yamada K., Izaki K., Sugimoto K., et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 57 (2003) 113-119
177. Seong J., Park H.C., Han K.H., et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 27 (2003) 30-35
178. Yeo W., Mok T.S., Zee B., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 (2005) 1532-1538
179. Yang T.S., Lin Y.C., Chen J.S., et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89 (2000) 750-756
180. Fuchs C.S., Clark J.W., Ryan D.P., et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 94 (2002) 3186-3191
181. Atiq O.T., Kemeny N., Niedzwiecki D., and Botet J. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer 69 (1992) 920-924
182. Seno H., Ito K., Kojima K., et al. Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. J Gastroenterol Hepatol 14 (1999) 811-816
183. Park J.Y., Ahn S.H., Yoon Y.J., et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110 (2007) 129-137
184. Ando E., Tanaka M., Yamashita F., et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95 (2002) 588-595
185. Yeung Y.P., Lo C.M., Liu C.L., et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 100 (2005) 1995-2004
186. Fujii T., Takayasu K., Muramatsu Y., et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 23 (1993) 105-109
187. Nakashima T., Okuda K., Kojiro M., et al. Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in ten years. Cancer 51 (1983) 863-877
188. Han K.H., Seong J., Kim J.K., et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 113 (2008) 995-1003
189. Ben-Josef E., Normolle D., Ensminger W.D., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 23 (2005) 8739-8747
190. Nerenstone S.R., Ihde D.C., and Friedman M.A. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15 (1988) 1-31
191. Burroughs A., and Samonakis D. Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?. Nat Clin Pract Gastroenterol Hepatol 1 (2004) 78-79
192. Abou-Alfa G.K. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol 33 6 Suppl 11 (2006) S79-S83
193. Villanueva A., Newell P., Chiang D.Y., et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27 (2007) 55-76
194. Vander Borght S., Komuta M., Libbrecht L., et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 28 (2008) 1370-1380
195. Stroescu C., Dragnea A., Ivanov B., et al. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointest Liver Dis 17 (2008) 411-417
196. Guo L., Guo Y., and Xiao S. Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology 72 (2007) 410-416
197. Ravry M.J., Omura G.A., and Bartolucci A.A. Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group trial. Cancer Treat Rep 68 (1984) 1517-1518
198. Zhu A.X. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?. Oncologist 11 (2006) 790-800
199. Lai C.L., Wu P.C., Chan G.C., et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62 (1988) 479-483
200. Gish R.G., Porta C., Lazar L., et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25 (2007) 3069-3075
201. Yang T.S., Wang C.H., Hsieh R.K., et al. A 2-stage phase II study of gemcitabie and doxorubicin in patients with advanced hepatocellular carcinoma. [abstract 670]. Proc Am Soc Clin Oncol 19 (2001) 168a
202. Lee J., Park J.O., Kim W.S., et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 54 (2004) 385-390
203. Al-Idrissi H.Y., Ibrahim E.M., Abdel Satir A., et al. Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin-C. Hepatogastroenterology 32 (1985) 8-10
204. Halm U., Etzrodt G., Schiefke I., et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 11 (2000) 113-114
205. Schmidinger M., Wenzel C., Locker G.J., et al. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 85 (2001) 1850-1852
206. Lind P.A., Naucler G., Holm A., et al. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Acta Oncol 46 (2007) 230-233
207. Pastorelli D., et al. A phase II study of pegylated liposomal doxorubicin (PLC) and gemcitabine (G) in the treatment of hepatocellular carcinoma (HCC) not suitable for locoregional therapy. [abstract]. J Clin Oncol 25 (2007) 218s
208. Shiu W., Mok S.D., O S.K., et al. Phase II trial of epirubicin in hepatoma. Cancer Treat Rep 70 (1986) 1035-1036
209. Davis R.B., Van Echo D.A., Leone L.A., and Henderson E.S. Phase II trial of mitoxantrone in advanced primary liver cancer: a Cancer and Leukemia Group B Study. Cancer Treat Rep 70 (1986) 1125-1126
210. Harvey W.H., Fleming T.R., Beltran G., et al. Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study. Cancer Treat Rep 71 (1987) 1111-1112
211. Okada S., Okazaki N., Nose H., et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50 (1993) 22-26
212. Tetef M., Doroshow J., Akman S., et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 13 (1995) 460-463
213. Yoshino M., Okazaki N., Yoshida T., et al. A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. Jpn J Clin Oncol 19 (1989) 120-122
214. Boige V., Taieb J., Hebbar M., et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 42 (2006) 456-459
215. Chao Y., Chan W.K., Birkhofer M.J., et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78 (1998) 34-39
216. Falcon-Lizaraso S., Leon-Chong J., Perazzo F., et al. Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unresectable hepatocellular carcinoma (HCC): preliminary results. Proc Am Soc Clin Oncol 22 (2004) 4083a
217. Patt Y.Z., Hassan M.M., Aguayo A., et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101 3 (2004) 578-586
218. Leung T.W., Patt Y.Z., Lau W.Y., et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5 (1999) 1676-1681
219. Louafi S., Boige V., Ducreux M., et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 109 (2007) 1384-1390
220. Li S., Niu Z., Tian H., et al. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology 54 (2007) 218-223
221. Merlin F., Santandrea G., Kildani B., et al. Gemcitabine plus oxaliplatin in patients with advanced hepatocellular carcinoma. [abstract 163]. ASCO 2007 GI Symposium (2007)
222. Bobbio-Pallavicini E., Porta C., Moroni M., et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 33 (1997) 1784-1788
223. Park S.H., Lee Y., Han S.H., et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 6 (2006) 3
224. Qin S., Wang Y.J., Wu Q., and Xing B.C. Phase II study of oxaliplatin +5-fluorouracil/leucovorin in patients with unresectable hepatocellular carcinoma. [abstract 151]. ASCO 2007 GI Symposium (2007)
225. Francavilla A., Polimeno L., DiLeo A., et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 9 (1989) 614-620
226. CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 352 (1998) 17-20
227. Barbare J.C., Bouche O., Bonnetain F., et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23 (2005) 4338-4346
228. Castells A., Bruix J., Bru C., et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 109 (1995) 917-922
229. Chow P.K., Tai B.C., Tan C.K., et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36 (2002) 1221-1226
230. Cheng A.L., Chen Y.C., Yeh K.H., et al. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 77 (1996) 872-877
231. Melia W.M., Johnson P.J., and Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71 (1987) 1213-1216
232. Raderer M., Pidlich J., Muller C., et al. A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocelluarl carcinoma. [letter]. Eur J Cancer 32A (1996) 2366
233. Cebon J., Findlay M., Hargreaves C., et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 95 (2006) 853-861
234. O'Neil B.H., Morse M.A., Allen J., et al. A phase II study of octreotide LAR in patients with advanced hepatocellular carcinoma and CLIP socre >3. [abstract 161]. ASCO 2007 GI Cancers Symposium (2007)
235. Calvisi D.F., Ladu S., Gorden A., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
236. Worns M.A., Weinmann A., Schuchmann M., and Galle P.R. Systemic therapies in hepatocellular carcinoma. Dig Dis 27 (2009) 175-188
237. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
238. Abou-Alfa G.K., Johnson P., Knox J., et al. Final results from a phase II (PhII) randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). [abstract 128]. 2008 Gastrointestinal Cancers Symposium (2008)
239. Siegel A.B., Cohen E.I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26 (2008) 2992-2998
240. Malka D., Dromain C., Farace F., et al. Bevacizumab in patients with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. [abstract 4570]. J Clin Oncol 25 Suppl (2007) 215s
241. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 1898-1903
242. Sun W., Haller D.G., Mykulowycz K., Rosen M., Soulen M., Capparo M., et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. [abstract]. J Clin Oncol 24 Suppl 18 (2007) 4574
243. Schwartz J.D., Schwartz M., Lehrer D., Cohen E., Sung M., Kinkhabwala M., et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol 24 June 20 Suppl (2006) 4144
244. Yau T., Chan P., Wong H., et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 72 Suppl 1 (2007) 67-71
245. Zhu A.X., Fuchs C.S., Clark J.W., Muzikansky A., Taylor K., Sheehan S., et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 10 (2005) 392-398
246. Alberts SR, Morlan BW, Kim GP, Pitot HC, Quevedo FJ, Dakhil SR, et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)-Interim review of toxicity [abstract 186]. 2007 Gastrointestinal Cancers Symposium.
247. Finn R.S., Kang Y., Park J., et al. Phase II, open label study of brivanib alaniate in patients (pts) with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy. [abstract 200]. 2009 Gastrointestinal Cancers Symposium (2009)
248. Zhu A.X., Sahani D.V., di Tomaso E., et al. A phase II study of sunitnib in patients with advanced hepatocellular carcinoma. [abstract 4637]. J Clin Oncol 25 (2007) 18S
249. Villanueva A., Chiang D.Y., Newell P., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (2008) 1972-1983
250. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., and Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 15 (2004) 8421-8425
251. Schiffer E., Housset C., Cacheux W., et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41 (2005) 307-314
252. Zhu A.X., Stuart K., Blaszkowsky L.S., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110 (2007) 581-589
253. Thomas M.B., Chadha R., Glover K., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110 (2007) 1059-1067
254. Kaseb O., Iwasaki M., Javle M., et al. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). [abstract 4522]. J Clin Oncol 27 Suppl (2009) 15s
255. Thomas M.B., Morris J.S., Chadha R., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27 (2009) 843-850